MEDFX
Live / Registered — Registered and renewed (as of 14 Jul 2025)
What this means for you
Registered since 27 Oct 2015. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 27 Oct 2025).
Record
- Serial number
- 86220538
- Registration number
- 4842066
- Mark type
- Stylized text
- Filed
- 13 Mar 2014
- Published for opposition
- 22 Jul 2014
- Registered
- 27 Oct 2015
- Next maintenance due
- 27 Oct 2025
- Attorney of record
- James David Johnson
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and dietary preparations for the treatment of pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases and metabolic disorders derived from plant extracts for therapeutical purposes
Owner
- Boston Research & Development, LLC, Norwood, MA, US
- Boston Research & Development, LLC, Norwood, MA, US
- Boston Research & Development, LLC, Norwood, MA, US
Prosecution history
- 14 Jul 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
- 14 Jul 2025 — REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
- 14 Jul 2025 — REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
- 14 Jul 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 12 Feb 2025 — TEAS SECTION 8 & 9 RECEIVED
- 28 Oct 2024 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 30 Dec 2021 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 30 Dec 2021 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 29 Dec 2021 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 27 Sept 2021 — TEAS SECTION 8 & 15 RECEIVED
- 27 Oct 2020 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 27 Oct 2015 — REGISTERED-PRINCIPAL REGISTER
- 24 Sept 2015 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 23 Sept 2015 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 21 Sept 2015 — STATEMENT OF USE PROCESSING COMPLETE